Table 3 Characteristics of real word-studies on anti-CGRP monoclonal antibodies in chronic migraine
From: CGRP-targeted medication in chronic migraine - systematic review
Study | Type of study Country | Sample | Inclusion criteria | MOH, % | Anti-CGRP mAb | Follow-up, months | Outcomes | Safety – Adverse events |
|---|---|---|---|---|---|---|---|---|
[32] | Monocentric Prospective Italy | 203 | Chronic migraine Failure of ≥ 3 preventive treatments | 84.8 | Erenumab (47.2%) Galcanezumab (36.5%) Fremanezumab (16.3%) | 12 | Mean reduction in MMD from baseline 8.4 to 13.2 ≥ 50% reduction in headache frequency: 36.4–56.8% | 7.9% |
[30] | Multicentric Prospetive Italy | 149 | Chronic migraine with MOH Failure of ≥ 3 preventive treatments plus failure of BTX-A | 100 | Erenumab 70 ◊ 140 mg | 3 | Reduction in MHDs from 25.4 ± 5.4 to 14.1 ± 8.6 ≥ 50% reduction in headache frequency 51% Percentage of cases converted from CM to EM: 64% Mean change in HIT-6 from baseline: -9.5 points | 32% |
[24] | Monocentric Prospective Italy | 303 | Chronic migraine with MOH | 100 | Erenumab (48.6%) Galcanezumab (20.6) Fremanezumab (30.6%) | 3–12 | ≥ 50% reduction in headache frequency 80% Percentage of cases converted from CM to EM: 88% Change in MIDAS: 56.5 to 13.1 | 19% |
[26] | Monocentric Prospective United Kingdom | 164 | Chronic migraine Failure of ≥ 3 preventive treatments | 54 | Erenumab | 6 | Mean reduction in MMD from baseline 7.5 days ≥ 50% reduction in headache frequency 49% Percentage of cases converted from CM to EM: 40% Mean change in HIT-6 from baseline: -7.5 points | 48% |
[25] | Monocentric Prospective Italy | 70 | Chronic migraine Failure of ≥ 4 preventive treatments | 91.4 | Erenumab 70 ◊ 140 mg | 6 | Reduction in MMDs from 21.1 +/- 0.7 to 11.4 +/- 0.9 days ≥ 50% reduction in headache frequency 53% Percentage of cases converted from CM to EM: 66% Mean change in HIT-6 from baseline: -6.4 points | 25.7% |